Independent Research
IBRX Analysis
11 pieces of research on ImmunityBio, Inc.. We find the signal management buried in the earnings call.
ImmunityBio Directors Sell $1.1M Before Key Bladder Data
Two ImmunityBio directors sold $1.12M in shares at $10.50–$10.75 in early October, at prices now 32–35% above the stock's current $7.95, weeks before November t…
Read analysis →ImmunityBio Directors Sold $3.9M Before Earnings Miss
Three ImmunityBio directors completed $3.92 million in open-market share sales between June 4 and July 2, before an August 4 earnings report that disclosed a 17…
Read analysis →ImmunityBio Drops 15% as Earnings Miss Overshadows 53% Growth
ImmunityBio reported 53% Q3 revenue growth but missed analyst estimates, triggering a 15% selloff to 9-month lows as persistent dilution fear outweighs top-line…
Read analysis →ImmunityBio Surges 11% as ANKTIVA Sales Drive 94% Revenue Growth
ImmunityBio's Q4 showed 94% YoY revenue growth driven by ANKTIVA commercial sales, lifting the stock 11%, but the company burns more cash than it earns and a 31…
Read analysis →